Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01969058 · ClinicalTrials.gov registry record · Phase 2

Effect of Isotretinoin on Immune Activation Among HIV-1 Infected Subjects With Incomplete CD4+ T Cell Recovery

A Phase 2 study of HIV-1-infection, sponsored by Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections.

Completed
Registry status
Phase 2
Development phase
76
Enrollment target
15
Study locations

NCT01969058 is a Phase 2 study of HIV-1-infection that has completed, run by Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections. The registered enrollment target is 76 participants, below the 350-participant average among 71 other HIV-1-infection trials with a reported enrollment target (78% lower). The trial reports 15 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01969058, a Phase 2 study of HIV-1-infection, has completed, sponsored by Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections.

COMPLETED
Registry status
Phase 2
Development phase
76 participants
Enrollment target
15
Study locations

Study Summary

This phase II study was done in HIV-infected participants on antiretroviral therapy to evaluate the effects of isotretinoin (a drug that is approved for use in the treatment of severe acne) on the immune system. The immune system helps the body fight infections. When the immune system is not working well, one may be at greater risk for diseases that are common in aging, like heart disease, weaker bones, and kidney disease.

Conditions Studied

HIV-1-infection

Interventions

  • DRUG Isotretinoin

Study Locations (15)

California

  • 601 University of California, Los Angeles CARE Center CRS - Los Angeles
  • 801 University of California, San Francisco HIV/AIDS CRS - San Francisco

Massachusetts

  • 101 Massachusetts General Hospital (MGH) CRS - Boston
  • 107 Brigham and Women's Hosp. ACTG CRS - Boston

North Carolina

  • 3201 Chapel Hill CRS - Chapel Hill
  • 3203 Greensboro CRS - Greensboro

Alabama

  • 31788 Alabama CRS - Birmingham

Missouri

  • 2101 Washington University Therapeutics (WT) CRS - St Louis

New Jersey

  • 31786 New Jersey Medical School Clinical Research Center CRS - Newark

New York

  • 31787 University of Rochester Adult HIV Therapeutic Strategies Network CRS - Rochester

Ohio

  • 2401 Cincinnati CRS - Cincinnati

Trial Details

FieldValue
Enrollment Target 76 participants
Start Date 2014-07-02
Est. Completion 2016-11
Phase Phase 2

Sponsor

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

45 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01969058

The ClinicalTrials.gov registry entry for NCT01969058 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 350-participant average among 71 other HIV-1-infection trials with a reported enrollment target (78% lower). The listed sponsor is Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, which has 45 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with HIV-1-infection appearing as the primary indexed condition, and to 1 intervention - of which Isotretinoin is the first listed.

NCT01969058 reports 15 study locations spanning 12 distinct geographic areas - top geographies include California, Massachusetts, North Carolina.

Frequently Asked Questions

What is clinical trial NCT01969058 about?

NCT01969058 is a clinical study titled "Effect of Isotretinoin on Immune Activation Among HIV-1 Infected Subjects With Incomplete CD4+ T Cell Recovery". This phase II study was done in HIV-infected participants on antiretroviral therapy to evaluate the effects of isotretinoin (a drug that is approved for use in the treatment of severe acne) on the immune system. The immune system helps the body fight infections. When the immune system is not working...

What is the current status of trial NCT01969058?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 76 participants. The study started on 2014-07-02. Estimated completion is 2016-11.

What conditions does trial NCT01969058 study?

This clinical trial studies the following conditions: HIV-1-infection.

What interventions are being tested in trial NCT01969058?

The interventions under investigation include: Isotretinoin (DRUG).

Who is sponsoring clinical trial NCT01969058?

This trial is sponsored by Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, which has 45 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01969058 being conducted?

This trial has 15 study locations across Alabama, California, Massachusetts, Missouri, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV-1-infection

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

HIV-1-infection

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.